Table 2.
Odds of no subsequent treatment following participation in first-line trials and survival following participation in second-line trials
| Characteristic | First-line therapy | Second-line therapy | Second-line therapy | ||||
|---|---|---|---|---|---|---|---|
| Odds of no subsequent treatment | Time to progression | Overall survival | |||||
| (n = 5289 [5121 evaluable]) |
(n = 7921 [7408 evaluable]) |
(n = 8280 [7764 evaluable]) |
|||||
| No. (%) | OR (95% CI) | P b | HR (95% CI) | P b | HR (95% CI) | P b | |
| Age at enrollment, per 10 y | 59.9 (10.7)a | 1.11 (1.02 to 1.21) | .01 | 0.97 (0.94 to 0.99) | .005 | 0.99 (0.97 to 1.02) | .62 |
| Age category | |||||||
| ≤70 y | 3889 (88.0) | – | – | – | – | – | – |
| >70 y | 744 (85.5) | – | – | – | – | – | – |
| Sex | |||||||
| Female | 1753 (88.2) | Referent | |||||
| Male | 2880 (87.2) | 1.15 (0.96 to 1.38) | .12 | 0.98 (0.94 to 1.04) | .54 | 0.97 (0.92 to 1.02) | .20 |
| ECOG PS | |||||||
| 0 | 2566 (90.4) | Referent | <.001 | <.001 | <.001 | ||
| 1 | 1815 (85.8) | 1.55 (1.30 to 1.84) | 1.22 (1.16 to 1.28) | 1.51 (1.43 to 1.59) | |||
| >1 | 115 (69.7) | 4.07 (2.85 to 5.82) | 1.59 (1.38 to 1.83) | 3.54 (3.13 to 4.02) | |||
| Metastasis | |||||||
| Lung | 1562 (87.4) | 1.03 (0.86 to 1.23) | .76 | 1.10 (1.04 to 1.18) | .003 | 1.08 (1.01 to 1.16) | .02 |
| Liver | 3421 (88.0) | 0.90 (0.75 to 1.09) | .29 | 1.36 (1.28 to 1.45) | <.001 | 1.62 (1.52 to 1.74) | <.001 |
| Peritoneum | 407 (88.1) | 0.92 (0.68 to 1.24) | .57 | 1.27 (1.03 to 1.57) | .03 | 1.42 (1.15 to 1.75) | .001 |
a
Values are mean (SD). CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group Performance Status; HR = hazard ratio; OR = odds ratio.
b
P values were calculated using a 2-sided Log rank test.